Sitagliptin/Metformin Merck 50 mg/1000 mg film-coated tablets 马耳他 - 英文 - Malta Medicines Authority

sitagliptin/metformin merck 50 mg/1000 mg film-coated tablets

merck healthcare kgaa frankfurter strasse 250, 64293 darmstadt, germany - sitagliptin, metformin hydrochloride - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

INEGY 10/20 Milligram Tablets 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

inegy 10/20 milligram tablets

merck sharp and dohme limited - ezetimibe, simvastatin - tablets - 10/20 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

INEGY 10/80 Milligram Tablets 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

inegy 10/80 milligram tablets

merck sharp and dohme limited - ezetimibe, simvastatin - tablets - 10/80 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

INEGY 10/40 Milligram Tablets 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

inegy 10/40 milligram tablets

merck sharp and dohme limited - ezetimibe, simvastatin - tablets - 10/40 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

INEGY 10/10 Milligram Tablets 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

inegy 10/10 milligram tablets

merck sharp and dohme limited - ezetimibe, simvastatin - tablets - 10/10 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

ATOZET 10 /10 Milligram Film Coated Tablet 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

atozet 10 /10 milligram film coated tablet

merck sharp and dohme limited - ezetimibe, micronized, atorvastatin, atorvastatin calcium trihydrate - film coated tablet - 10 /10 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

ATOZET 10 / 20 Milligram Film Coated Tablet 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

atozet 10 / 20 milligram film coated tablet

merck sharp and dohme limited - ezetimibe, micronized, atorvastatin calcium trihydrate - film coated tablet - 10 / 20 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

ATOZET 10 / 40 Milligram Film Coated Tablet 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

atozet 10 / 40 milligram film coated tablet

merck sharp and dohme limited - ezetimibe, micronized, atorvastatin, atorvastatin calcium trihydrate - film coated tablet - 10 / 40 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

ATOZET 10 / 80 Milligram Film Coated Tablet 爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

atozet 10 / 80 milligram film coated tablet

merck sharp and dohme limited - ezetimibe, micronized, atorvastatin, atorvastatin calcium trihydrate - film coated tablet - 10 / 80 milligram - hmg coa reductase inhibitors in combination with other lipid modifying agents

ZOSTAVAX- zoster vaccine live injection, powder, lyophilized, for suspension
STERILE DILUENT- sterile water injection 美国 - 英文 - NLM (National Library of Medicine)

zostavax- zoster vaccine live injection, powder, lyophilized, for suspension sterile diluent- sterile water injection

merck sharp & dohme llc - varicella-zoster virus strain oka/merck live antigen (unii: gpv39zgd8c) (varicella-zoster virus strain oka/merck live antigen - unii:gpv39zgd8c) - varicella-zoster virus strain oka/merck live antigen 19400 [pfu] in 0.65 ml - zostavax® is a live attenuated virus vaccine indicated for prevention of herpes zoster (shingles) in individuals 50 years of age and older. limitations of use of zostavax: - zostavax is not indicated for the treatment of zoster or postherpetic neuralgia (phn). - zostavax is not indicated for prevention of primary varicella infection (chickenpox). do not administer zostavax to individuals with a history of anaphylactic/anaphylactoid reaction to gelatin, neomycin or any other component of the vaccine. neomycin allergy manifested as contact dermatitis is not a contraindication to receiving this vaccine. {1} do not administer zostavax to individuals who are immunodeficient or immunosuppressed due to disease or therapy, as serious or fatal disseminated vaccine strain varicella-zoster virus disease may occur. causes of immunodeficiency or immunosuppression may include, but are not limited to, primary or acquired immunodeficiency states, aids or other clinical manifestations of infection with human immunodeficiency